Short Bowel Syndrome (SBS) results from extensive intestinal resection due to chronic Inflammatory Bowel Disease (IBD), acute events (e.g. mesenteric infarction) or congenital abnormalities.
It is estimated that between 20,000 and 40,000 people are living with short bowel syndrome in the United States and Europe.
Intestinal failure (IF), a common consequence of SBS, occurs when less than 200cm of functional intestine remains. IF is a life-threatening complication characterized by malabsorption and malnutrition, infections, blood clots and poor quality of life. Patients with SBS-IF require life-long parenteral support, which involves providing the body’s nutritional needs via intravenous drip rather than eating or drinking.
The current standard for care for SBS includes:
Our Apraglutide product candidate, a next-generation, synthetic GLP-2 analog with a potentially best-in-class profile, aims to improve on:
A Phase 1 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) clinical trial was successfully completed in healthy volunteers. Two Phase 2 studies in two distinct SBS populations – patients with Intestinal Failure and patients with Intestinal Insufficiency – are underway.